IFRX InflaRx N.V.

1.560USD-1.27%Mkt Cap: 229.89M $P/E: —

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimm…

Key Statistics

Company
Market Cap229.89M USD
Enterprise Value75.16M USD
Revenue (TTM)-10.10K USD
Gross Profit-7.24M USD
Net Income (TTM)-45.63M USD
Revenue/Share0.00 USD
Last Price1.560 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees65
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.07
PEG—
EV/EBITDA-2.11
EV/Revenue-7440.89
P/S-23051.36
P/B1.42
EPS (TTM)-0.58
EPS (Forward)-0.39
52W Range
0.798035% of range2.949
52W High2.949 USD
52W Low0.7980 USD
Profitability
Gross Margin-24677.94%
Oper. Margin352965.00%
EBITDA Margin0.00%
Profit Margin-155582.08%
ROE-109.81%
ROA-82.65%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-35.31M USD
CapEx (TTM)115.69K USD
FCF Margin42690.19%
FCF Yield-1.88%
Net Debt-157.68M USD
Net Debt/EBITDA4.42
Balance Sheet
Debt/Equity0.02
Current Ratio8.22
Quick Ratio7.95
Book Value/Sh1.12 USD
Cash/Share1.08 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.675 USD
Upside (mean)+392.0%
Target Range2.924 USD – 13.65 USD
2.924+392.0% to mean13.65
# Analysts9
Ownership
Shares Out.147.37M
Float98.11M
Insiders2.95%
Institutions70.39%
Short Interest
Short Ratio15.1d
Short % Float8.96%
Short % Out.8.22%
Shares Short12.11M
Short (prev mo.)9.46M
Technical
SMA 501.992 (-21.7%)
SMA 2001.591 (-2.0%)
Beta2.61
S&P 52W Chg16.45%
Avg Vol (30d)542.26K
Avg Vol (10d)453.59K
Technical Indicators
RSI (14)28.5
MACD-0.1153
MACD Signal-0.0673
MACD Hist.-0.0480
BB Upper2.300 USD
BB Middle1.917 USD
BB Lower1.533 USD
BB Width40.07%
ATR (14)0.1242 USD
Vol Ratio (20d)0.97x